Trials / Sponsors / New River Pharmaceuticals
New River Pharmaceuticals
Industry · 6 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders | Phase 3 | 2006-07-01 |
| Completed | Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADH Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders | Phase 3 | 2006-05-01 |
| Completed | Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulan Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders | Phase 1 / Phase 2 | 2006-01-01 |
| Completed | Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders | Phase 2 | 2005-09-01 |
| Completed | Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD Attention Deficit Hyperactivity Disorder | Phase 3 | 2004-10-01 |
| Completed | NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD Attention Deficit Disorder With Hyperactivity | Phase 2 | 2004-09-01 |